MedTrace Logo

Pharmacokinetic Comparison of XS003 and Tasigna

NCT02068898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-11-11

No results posted yet for this study

Summary

The study will assess bioavailability of XS003 given as a single oral dose compared to Tasigna® given as a single oral dose in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

XS003

DRUG

Tasigna

Sponsors & Collaborators

  • XSpray Microparticles

    lead INDUSTRY

Principal Investigators

  • XSpray Microparticles · XSpray Microparticles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-03-31
Completion
2014-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02068898 on ClinicalTrials.gov